A three-armed randomized controlled trial assessing the efficacy and safety of Icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19
Latest Information Update: 17 Feb 2021
At a glance
- Drugs Complement C1 inhibitor protein (Primary) ; Icatibant (Primary)
- Indications COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms ITHACA
- 17 Feb 2021 New trial record
- 20 Jan 2021 Trial design published in the Trials